Systemic inequalities continue to influence recommended treatments, even when the same drugs are equally effective for people of all races. In fact, there is good reason to think that blacks and Latinos are particularly suitable candidates for the GLP-1.
“The presence of cardiovascular disease, such as a history of heart attack, stroke, or heart failure, is an aspect to consider when considering GLP-1, as it has proven benefits in reducing all of these events in diabetic patients,” says Dr. Rao. For this reason, he added, it is important for doctors to take a good medical history and uncover any information that may be related to these symptoms.
People with a high BMI and high A1C levels (measured average blood sugar levels over the past three months) are also good candidates for GLP-1, Rao said. This is especially true because other type 2 diabetes drugs are not able to lower A1C levels as well as these drugs.
One study found that treatment with semaglutide (a type of GLP-1) reduced the risk of major cardiovascular events by 18 percent and the risk of death from any cause by 20 percent in patients with type 2 diabetes and CKD.